Q3 EPS Estimate for Ocular Therapeutix Decreased by Analyst

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for Ocular Therapeutix to (0.39), indicating a decrease from the previous estimate of (0.37), while maintaining a "Buy" rating and a $15.00 target price.
• The company reported a Q2 2025 EPS of (0.39), which was $0.04 lower than analysts' expectations, despite exceeding revenue estimates of $13.46 million against an expected $13.12 million.
• Ocular Therapeutix has a consensus "Buy" rating from analysts, with an average price target of $17.17 as several research firms adjust their price objectives for the stock.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - HC Wainwright lowered their Q3 2025 earnings estimates for Ocular Therapeutix in a research note issued on Wednesday, August 6th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will post earnings per share of ($0.39) for the quarter, down from their prior forecast of ($0.37). HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix's Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.53) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.49) EPS.

OCUL has been the subject of a number of other reports. Scotiabank reduced their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Wednesday, August 6th. Needham & Company LLC lifted their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $17.20.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded down $0.41 during midday trading on Friday, reaching $12.15. 1,259,875 shares of the company traded hands, compared to its average volume of 1,787,509. The firm's 50 day simple moving average is $10.26 and its two-hundred day simple moving average is $8.41. Ocular Therapeutix has a 1-year low of $5.78 and a 1-year high of $12.68. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. The firm has a market cap of $2.11 billion, a PE ratio of -9.45 and a beta of 1.49.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The firm had revenue of $13.46 million during the quarter, compared to analyst estimates of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. Ocular Therapeutix's revenue for the quarter was down 17.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) EPS.

Insider Activity

In related news, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider directly owned 3,499,099 shares in the company, valued at $25,123,530.82. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 29,079 shares of company stock worth $208,739. Insiders own 2.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. raised its holdings in Ocular Therapeutix by 44.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company's stock valued at $38,116,000 after acquiring an additional 1,600,000 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in Ocular Therapeutix during the 1st quarter worth $9,632,000. Point72 Asset Management L.P. boosted its position in Ocular Therapeutix by 43.9% in the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock valued at $25,073,000 after buying an additional 895,304 shares during the last quarter. Peregrine Capital Management LLC purchased a new position in Ocular Therapeutix in the 1st quarter valued at about $6,212,000. Finally, Millennium Management LLC acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at about $3,819,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.